Cancer-care startup Oncar has raised Rs 27 crore (around $4 million) in a Series A funding round led by Elevation Capital. The round also saw participation from Huddle Ventures, Lotus Herbal Group, SteerXand Caret Capital.
The fresh infusion comes as investor interest in oncology-focused startups gathers pace in India, driven by rising cancer incidence, growing healthcare awareness, and the need for more standardised treatment pathways. For Oncare, this round represents not just capital, but validation of its distributed cancer-care model.
Credits: Ascendants
Oncare plans to deploy the newly raised funds across three key priorities: geographic expansion, technology infrastructure, and operational strengthening.
The company is looking to expand beyond its existing presence in Delhi NCR into other metro cities, while also tapping tier-II and tier-III markets. This dual-market strategy signals an ambition to balance scale with accessibility — reaching both high-demand urban centres and underserved regions where oncology infrastructure remains limited.
A portion of the funds will also go toward upgrading its technology backbone. Oncare aims to streamline clinical operations, standardise protocols across centres, and enhance patient experience through better coordination and data systems. In oncology, where treatment journeys are long and complex, operational efficiency can directly impact outcomes and affordability.
Founded in 2023 by Amar Sneh and Deepak KumarOncare operates a distributed oncology care model. Instead of building large, standalone cancer hospitals — which are capital-intensive and time-consuming — the startup partners with accredited hospitals to integrate medical, surgical, and radiation oncology services under one coordinated platform.
This approach allows Oncare to plug into existing hospital infrastructure while standardising cancer treatment protocols across locations. The model is designed to be asset-light and scalable, enabling faster expansion without the heavy upfront investments typical of traditional hospital chains.
By embedding oncology services within accredited partner hospitals, Oncare positions itself as a clinical and operational layer that enhances care delivery rather than duplicating infrastructure.
Currently, Oncare operates four centres across Delhi NCR. In just two years since launch, the company says it has built a multi-centre oncology platform — an achievement that underscores its execution focus in the early stages.
The next chapter, however, will test its ability to replicate this playbook in new geographies. Expanding into additional metros will require forging hospital partnerships, hiring specialised oncologists, and ensuring consistent treatment standards. Moving into tier-II and tier-III cities adds another layer of complexity, including pricing sensitivity and infrastructure gaps.
If successful, Oncare could help bridge the disparity between high-quality oncology care in major cities and limited access in smaller towns.
This Series A follows an earlier $1 million seed round led by Huddle Ventures and other investors. That early capital helped Oncare establish its Delhi NCR footprint and validate its distributed model.
The new funding round, significantly larger in size, is geared toward scaling rather than proving the concept. It reflects growing investor confidence in healthcare startups that focus on operational excellence and network-led expansion rather than asset-heavy growth.
Credits: The Hindu Business Line
India’s cancer burden continues to rise, but access to standardised and affordable treatment remains uneven. Large tertiary hospitals are often concentrated in metros, while smaller cities face shortages of specialised oncology services.
Oncare’s distributed model offers an alternative path: leveraging existing accredited hospitals while introducing uniform protocols, technology integration, and coordinated care. This capital-efficient structure could allow faster, wider penetration compared to building new cancer hospitals from scratch.
However, the real story will lie in execution. Can Oncare maintain quality and consistency across diverse markets? Can it scale partnerships without diluting standards? And can technology truly streamline complex oncology workflows?
As investor interest in oncology startups intensifies, Oncare’s Series A marks another milestone in the sector’s evolution. The coming months will reveal whether its distributed network can deliver on the promise of accessible, standardised cancer care — at scale.
